ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2016, Vol. 25 ›› Issue (5): 420-424.DOI: 10.3969/cndt.j.issn.1006-298X.2016.05.004

• 论文 • 上一篇    下一篇

Alport综合征患儿血清可溶性尿激酶型纤溶酶原激活物受体水平变化的临床意义

  

  • 出版日期:2016-10-28 发布日期:2016-11-03

Change of serum soluble urokinasetype plasminogen activator receptor in children with Alport syndrome

  • Online:2016-10-28 Published:2016-11-03

摘要:

目的:初步探讨Alport综合征患儿血清可溶性尿激酶型纤溶酶原激活物受体(suPAR)的水平及其临床意义。
方法:入选34例Alport综合征患儿,11例原发性局灶节段性肾小球硬化(FSGS)患儿疾病对照以及13例健康对照儿童,采用ELISA法检测血清suPAR的浓度,并收集患儿同期临床资料。
结果:Alport综合征患儿平均年龄(956±465)岁,男性28例、女性6例,X连锁显性遗传型24例、常染色体隐性遗传型10例。Alport综合征组血清suPAR浓度显著高于健康对照组[(3 89665±97934) pg/ml vs (2 74762±27759) pg/ml,P<0000 1],但低于原发性FSGS组(4 61927±1 04356) pg/ml(P=0042)。Alport综合征患儿血清suPAR浓度与24h尿蛋白定量(r=0400,P=0021)、血清肌酐(SCr)水平(r=0410,P=0016)呈正相关。Alport综合征Ccr<90 ml/(min·173m2)组患儿的血清suPAR的浓度显著高于Ccr≥90 ml/(min·173m2)组(P<0000 1)。Alport综合征患儿血清suPAR浓度与年龄、性别、遗传型等无明显相关性。原发性FSGS患儿血清suPAR浓度与Ccr呈负相关(r=-0833,P=0008),与24h尿蛋白定量、SCr水平无明显相关性。
结论:Alport综合征患儿血清suPAR浓度升高,提示该指标是一种新的标志物,可与蛋白尿、SCr共同用来反映肾脏损伤程度。

关键词: Alport综合征, 可溶性尿激酶型纤溶酶原激活物受体, 慢性肾脏病, 蛋白尿

Abstract:

Objective:To investigated the role of serum levels of soluble urokinase plasminogen activator receptor (suPAR) in children with Alport syndrome.
Methodology:34 children with Alport syndrome were enrolled into this study. 11 children with primary FSGS were as disease controls and 13 healthy children were as normal controls. The clinical and pathological data were collected at the time of take the serum samples. The serum suPAR were measured using commercially available kits. The relationship between  levels and  protienuria, serum creatinine, creatinine clearance rate, and other clinical and pathological data were analyzed.
Results:The average age of children with Alport syndrome was 956±465 ys. Male and female rate was 28∶6. There were 24 children with Xlinked Alport syndrome, and 10 with autosomal recessive Alport syndrome. 12 children were combined with hearing loss. The mean level of serum suPAR was significantly elevated in children with Alport syndrome compared to normal controls [(3 89665±97934) pg/ml vs (2 74762±27759) pg/ml, P<0000 1]. The mean level of serum suPAR in children with primary FSGS was (4 61927±1 04356) pg/ml. Furthermore, the serum suPAR levels in children with Alport syndrome were positively correlated with the 24 hours proteinuria (r=0400 0, P=0021 1) and serum creatinine levels (r=0410 1, P=0016 0). The serum suPAR level was significantly higher in Alport children with Ccr<90 (ml/min·173m2) than in Alport children with Ccr≥90 (ml/min·173m2) (P<0000 1). The serum suPAR levels in children with primary FSGS were negatively correlated with Ccr (r=-0833 3,P=0008 3).
Conclusion:An elevated level of suPAR was detected in children with Alport syndrome. The serum suPAR level may serve as a new marker associated with renal damage.